Posted inInternal Controls

Senators File Amendment to SOX 404(b) Exemption

Gear up for more fighting on SOX 404: An amendment to Senate financial reform bill would exempt companies with less than $150 million in public float from Sarbanes-Oxley’s outside auditor attestation requirement, which would include some companies already complying with the provision. Sen. Kay Bailey Hutchison (R-Texas) and Sen. Mary Landrieu (D-La.), chair of the […]

Posted inRegulatory Enforcement

Ruling Expands Scope of Whistleblower Protections

A federal judge in Massachusetts has fired a dramatic new volley in the battles over who can file whistleblower retaliation claims under Section 806 of the Sarbanes-Oxley Act, ruling that two employees of a private contractor to Fidelity Investments can pursue retaliation complaints against Fidelity, because the business ultimately serves investors in public companies. The […]

Posted inRegulatory Enforcement

Healthcare Reform Expands False Claims Liability

The healthcare reform law passed by Congress last month has yet another surprise for corporate legal and compliance departments: It allows yet more whistleblower lawsuits to be filed against corporations under the False Claims Act. Formally known as the Patient Protection and Affordable Care Act, the healthcare law sharply narrows the definition of “publicly disclosed […]

Posted inRegulatory Enforcement

Whistleblowers Gain Ground on Retaliation Suits

Corporate whistleblowers suing employers for alleged retaliation may be gaining more traction in the legal system, with two plaintiffs recently winning reinstatement of their jobs and back pay through the Department of Labor. The decisions have caused a stir in corporate legal circles because whistleblowers have rarely won retaliation claims filed under Section 806 of […]

Posted inRegulatory Enforcement

Innospec Settlement Shows Latest FCPA Thinking

Ethics and compliance officers might want to pay special attention to the Justice Department’s recent settlement of Foreign Corrupt Practices Act charges against chemical company Innospec, which is emerging as the latest cautionary tale about overseas bribery, self-disclosure, and global anti-corruption enforcement. Innospec, a $600 million chemical company based in Newark, Del., pleaded guilty March […]

Gift this article